The ongoing uncertainty about the place of transcatheter aortic valve replacement (TAVR) was addressed by emerging evidence presented in part at the American College of Cardiology meeting (16–18 March 2019 New Orleans) and in the New England Journal of Medicine. Edward Scientific’s PARTNER 3 trial [1] and Medtronic’s Evolut Low Risk Trial (LRT) [2] were both simultaneously presented and published in the New England Journal of Medicine
Importance: Transcatheter aortic valve replacement (TAVR) is now a well-accepted alternative to surg...
BACKGROUND: There is a paucity of prospective and controlled data on the comparative effectivene...
BACKGROUND: The comparative benefits and harms of transcatheter aortic valve implantation (TAVI) an...
The ongoing uncertainty about the place of transcatheter aortic valve replacement (TAVR) was address...
Background The recent approval of transcatheter aortic valve replacement (TAVR) in patients with low...
BACKGROUND: Transcatheter aortic-valve replacement (TAVR) is an alternative to surgery in patients w...
Background: The aim of this meta-analysis was to compare the impact of transcatheter aortic valve im...
The PARTNER group recently published a comparison between the latest generation SAPIEN 3 transcathet...
Abstract Objective[AM1] : To compare the safety and efficacy of transcatheter aortic valve replac...
AbstractBackgroundTranscatheter aortic valve replacement (TAVR) is an option in certain high-risk su...
Transcatheter aortic valve replacement (TAVR) is a well-established technique for the treatment of s...
Recently, two randomized trials, the PARTNER 3 and the Evolut Low Risk Trial, independently demonstr...
Abstract Importance: Transcatheter aortic valve replacement (TAVR) has been shown to be a valid alt...
BACKGROUND: Transcatheter aortic valve replacement (TAVR) is now the standard of care for patients w...
Background: Data on outcomes of transcatheter aortic valve replacement (TAVR) in the Middle East, pa...
Importance: Transcatheter aortic valve replacement (TAVR) is now a well-accepted alternative to surg...
BACKGROUND: There is a paucity of prospective and controlled data on the comparative effectivene...
BACKGROUND: The comparative benefits and harms of transcatheter aortic valve implantation (TAVI) an...
The ongoing uncertainty about the place of transcatheter aortic valve replacement (TAVR) was address...
Background The recent approval of transcatheter aortic valve replacement (TAVR) in patients with low...
BACKGROUND: Transcatheter aortic-valve replacement (TAVR) is an alternative to surgery in patients w...
Background: The aim of this meta-analysis was to compare the impact of transcatheter aortic valve im...
The PARTNER group recently published a comparison between the latest generation SAPIEN 3 transcathet...
Abstract Objective[AM1] : To compare the safety and efficacy of transcatheter aortic valve replac...
AbstractBackgroundTranscatheter aortic valve replacement (TAVR) is an option in certain high-risk su...
Transcatheter aortic valve replacement (TAVR) is a well-established technique for the treatment of s...
Recently, two randomized trials, the PARTNER 3 and the Evolut Low Risk Trial, independently demonstr...
Abstract Importance: Transcatheter aortic valve replacement (TAVR) has been shown to be a valid alt...
BACKGROUND: Transcatheter aortic valve replacement (TAVR) is now the standard of care for patients w...
Background: Data on outcomes of transcatheter aortic valve replacement (TAVR) in the Middle East, pa...
Importance: Transcatheter aortic valve replacement (TAVR) is now a well-accepted alternative to surg...
BACKGROUND: There is a paucity of prospective and controlled data on the comparative effectivene...
BACKGROUND: The comparative benefits and harms of transcatheter aortic valve implantation (TAVI) an...
Add to ORKG